Concepedia

Author

Daniel Dubé

Merck Canada Inc. (Canada)

Also Known As

D Dubé, D. DUBE, D. Dubé, Daniel Dube, Daniel Dubé, Daniel Dubé,, Daniel. Dube, Dubé, Daniel

55

Publications

2K

Citations

22

H-Index

47

Concepts

All Affiliations

Merck Canada Inc. (Canada)Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military AcademyUniversité de Montréal
DD

About

Daniel Dubé is an author at Merck Canada Inc. (Canada) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

15

19

806

2

Natural Sciences

12

14

865

3

Engineering

4

4

327

4

Health Sciences

1

1

13

5

Allergy

1

1

30

Daniel Dubé

×

33

Publications

2K

Citations

22

H-Index

YearCitations

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau,

Journal of Pharmacology and Experimental Therapeutics

2001

456

Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Daniel Dubé, Marc Blouin, Christine Brideau,

Bioorganic & Medicinal Chemistry Letters

1998

271

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors

Richard W. Friesen, Christine Brideau, Chi Chung Chan,

Bioorganic & Medicinal Chemistry Letters

1998

128

Reductive N-alkylation of amides, carbamates and ureas

Daniel Dubé, Andrew A. Scholte

Tetrahedron Letters

1999

114

Synthesis of (+)-avermectin B1a

Stephen Hanessian, Antonio Ugolini, Daniel Dubé,

Journal of the American Chemical Society

1986

109

Facile access to (<i>S</i>)-1,2,4-butanetriol and its derivatives

Stephen Hanessian, Antonio Ugolini, Daniel Dubé,

Canadian Journal of Chemistry

1984

97

Progress in natural product chemistry by the chiron and related approaches - synthesis of avermectin B1a

Stephen Hanessian, Antonio Ugolini, Paul J. Hodges,

Pure and Applied Chemistry

1987

64

Dioxabicyclooctanyl Naphthalenenitriles as Nonredox 5-Lipoxygenase Inhibitors:  Structure−Activity Relationship Study Directed toward the Improvement of Metabolic Stability

Daniel Delorme, Yves Ducharme, Christine Brideau,

Journal of Medicinal Chemistry

1996

62

Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors

Susana Liu, Alain Veilleux, Lei Zhang,

Journal of Pharmacology and Experimental Therapeutics

2005

58

Catalytic Inactivation of Protein Tyrosine Phosphatase CD45 and Protein Tyrosine Phosphatase 1B by Polyaromatic Quinones

Qingping Wang, Daniel Dubé, Richard W. Friesen,

Biochemistry

2004

55

Page 1